BriaCell Therapeutics Corp.
BCTX | NASDAQ
$3.99
-$0.16 (-3.86%)
Sep 22, 2026, 2:20 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Jul 30, 2025 | FY 2024 Jul 30, 2024 | FY 2023 Jul 30, 2023 | FY 2022 Jul 30, 2022 | FY 2021 Jul 30, 2021 | FY 2020 Jul 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 147.89K | 82.57K | 15.53K | 15.14K | 15.58K | 18.74K |
Gross Profit | -147.89K | -82.57K | -15.53K | -15.14K | -15.58K | -18.74K |
Operating Income | -37.73M | -33.34M | -31.08M | -19.61M | -8.72M | -5.28M |
Interest Income | 166.38K | 283.61K | 1.2M | 173.86K | 4.02K | n/a |
Pretax Income | -36.83M | -4.93M | -27.11M | -34.42M | -17.27M | -5.39M |
Net Income | -36.49M | -4.79M | -27.11M | -34.42M | -17.27M | -4.94M |
Selling & General & Admin | 8.08M | 6.15M | 10.6M | 9.32M | 6.19M | 1.84M |
Research & Development | 29.5M | 27.19M | 20.48M | 10.29M | 2.53M | 2.98M |
Other Expenses | n/a | n/a | n/a | n/a | -3.17K | n/a |
Operating Expenses | 37.58M | 33.34M | 31.08M | 19.61M | 8.72M | 4.82M |
Interest Expense | 51.29K | n/a | n/a | 1.24K | 100.22K | 36.2K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 37.73M | 33.34M | 31.08M | 19.61M | 8.72M | 4.84M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.88M | 1.1M | 1.04M | 1.03M | 301.31K | 47.59K |
Shares Outstanding (Diluted) | 1.88M | 1.1M | 1.04M | 1.03M | 301.31K | 47.59K |
EPS (Basic) | -62.60 | -43.01 | -192.55 | -257.58 | -13.50 | -5.64 |
EPS (Diluted) | -62.60 | -43.01 | -195 | -259.50 | -13.50 | -5.64 |
EBITDA | -37.58M | -4.85M | -31.06M | -34.4M | -17.15M | -4.82M |
EBIT | -37.73M | -4.93M | -31.08M | -34.42M | -17.17M | -4.84M |
Depreciation & Amortization | 147.89K | 83.93K | 20.39K | 19.59K | 19.07K | 18.74K |
Add to Watchlist
Select watchlists to add or remove BCTX